Robinson Value Management Ltd. acquired a new position in shares of Abbott Laboratories (NYSE:ABT) during the fourth quarter, Holdings Channel reports. The fund acquired 12,406 shares of the healthcare product maker’s stock, valued at approximately $477,000.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Patten Group Inc. boosted its position in shares of Abbott Laboratories by 66.0% in the third quarter. Patten Group Inc. now owns 2,516 shares of the healthcare product maker’s stock worth $103,000 after buying an additional 1,000 shares in the last quarter. Kanaly Trust Co boosted its position in shares of Abbott Laboratories by 3.7% in the third quarter. Kanaly Trust Co now owns 2,584 shares of the healthcare product maker’s stock worth $109,000 after buying an additional 91 shares in the last quarter. Guidant Wealth Advisors acquired a new position in shares of Abbott Laboratories during the third quarter worth about $130,000. Bruderman Asset Management LLC boosted its position in shares of Abbott Laboratories by 0.3% in the third quarter. Bruderman Asset Management LLC now owns 3,124 shares of the healthcare product maker’s stock worth $132,000 after buying an additional 10 shares in the last quarter. Finally, Apriem Advisors boosted its position in shares of Abbott Laboratories by 4.2% in the third quarter. Apriem Advisors now owns 3,419 shares of the healthcare product maker’s stock worth $145,000 after buying an additional 139 shares in the last quarter. Hedge funds and other institutional investors own 62.20% of the company’s stock.

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Shares of Abbott Laboratories (NYSE:ABT) opened at 44.20 on Friday. The firm has a 50-day moving average of $41.31 and a 200 day moving average of $41.16. The company has a market cap of $65.08 billion, a price-to-earnings ratio of 47.17 and a beta of 0.97. Abbott Laboratories has a 12 month low of $36.76 and a 12 month high of $45.79.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Monday, February 6th. The healthcare product maker reported $0.65 EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.65. The business earned $5.33 billion during the quarter, compared to analyst estimates of $5.41 billion. Abbott Laboratories had a net margin of 6.71% and a return on equity of 15.74%. The company’s revenue for the quarter was up 2.8% on a year-over-year basis. During the same period in the prior year, the business earned $0.62 EPS. On average, analysts expect that Abbott Laboratories will post $2.45 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which was paid on Wednesday, February 15th. Investors of record on Friday, January 13th were paid a $0.265 dividend. This represents a $1.06 annualized dividend and a dividend yield of 2.40%. This is a positive change from Abbott Laboratories’s previous quarterly dividend of $0.26. The ex-dividend date was Wednesday, January 11th. Abbott Laboratories’s dividend payout ratio (DPR) is presently 113.98%.

“Robinson Value Management Ltd. Takes Position in Abbott Laboratories (ABT)” was originally published by Daily Political and is owned by of Daily Political. If you are reading this report on another publication, it was copied illegally and reposted in violation of United States & international copyright legislation. The legal version of this report can be accessed at http://www.dailypolitical.com/2017/02/17/robinson-value-management-ltd-takes-position-in-abbott-laboratories-abt.html.

A number of research analysts have recently issued reports on the stock. Zacks Investment Research upgraded shares of Abbott Laboratories from a “hold” rating to a “buy” rating and set a $46.00 price objective for the company in a report on Tuesday, January 10th. RBC Capital Markets reduced their price objective on shares of Abbott Laboratories from $48.00 to $46.00 and set an “outperform” rating for the company in a report on Thursday, January 26th. Jefferies Group LLC boosted their price target on shares of Abbott Laboratories from $47.00 to $48.00 and gave the stock a “buy” rating in a report on Friday, January 20th. TheStreet cut shares of Abbott Laboratories from a “buy” rating to a “hold” rating in a report on Friday, December 2nd. Finally, Royal Bank Of Canada cut their price target on shares of Abbott Laboratories from $48.00 to $46.00 and set an “outperform” rating on the stock in a report on Thursday, January 26th. Five analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. Abbott Laboratories presently has a consensus rating of “Buy” and an average target price of $47.38.

In other Abbott Laboratories news, insider Robert B. Ford purchased 12,775 shares of the firm’s stock in a transaction that occurred on Wednesday, December 14th. The stock was bought at an average cost of $39.09 per share, for a total transaction of $499,374.75. Following the purchase, the insider now directly owns 51,532 shares in the company, valued at $2,014,385.88. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Brian J. Blaser purchased 15,580 shares of the firm’s stock in a transaction that occurred on Tuesday, December 20th. The stock was acquired at an average price of $38.45 per share, with a total value of $599,051.00. Following the completion of the purchase, the insider now owns 129,782 shares in the company, valued at $4,990,117.90. The disclosure for this purchase can be found here. 0.26% of the stock is owned by company insiders.

About Abbott Laboratories

Abbott Laboratories (Abbott) is engaged in the discovery, development, manufacture and sale of a line of healthcare products. The Company operates in four business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products.

5 Day Chart for NYSE:ABT

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT).

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.